Consort Medical sees profits slide after turbulent year
This article was originally published in Clinica
Executive Summary
Pfizer’s decision to cut short its ailing Exubera inhaled insulin business has hit Consort Medical, the manufacturer of the inhaler device, hard. In its financial results for fiscal 2008, Consort’s product revenues were flat at around £126.5m ($251.1m) and net income plunged to £2.6m, a significant drop from the £9.8m recorded in fiscal 2007.